David R. Gandara, MD

A number of randomized clinical trials and meta-analyses now support the conclusion that combined modality regimens that include cisplatin (Platinol)-based chemotherapy improve survival in stage III non–small-cell lung

The article by Drs. Gordon and Vokes provides the reader with a comprehensive overview of the treatment of locally advanced unresectable non–small-cell lung cancer (NSCLC) with chemotherapy and radiation therapy. The authors